The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lenvatinib's efficacy in heavily pre-treated metastatic renal cell carcinoma: Insights from a European multicenter study.
 
Javier Gavira
Speakers' Bureau - Astellas Pharma; LEO Pharma
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb/Roche; Ipsen; Lilly; Novartis; Roche
 
Edouard Auclin
Honoraria - Genzyme
Travel, Accommodations, Expenses - Mundipharma
 
Macarena Rey
No Relationships to Disclose
 
Pritha Roy
No Relationships to Disclose
 
Jose Tapia
Speakers' Bureau - Eisai
Travel, Accommodations, Expenses - Lilly; Pfizer; Roche/Genentech
 
Paula Nay
No Relationships to Disclose
 
Armelle Vinceneux
Consulting or Advisory Role - AAA/Endocyte/Novartis; Ipsen; Loxo/Lilly
Research Funding - Astellas Pharma (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; MSD Oncology; Pfizer
 
Simon Nannini
No Relationships to Disclose
 
Adela Randis
No Relationships to Disclose
 
Delphine Borchiellini
No Relationships to Disclose
 
Guillermo de Velasco
Honoraria - Astellas Pharma; BMS; Ipsen; Pfizer
Consulting or Advisory Role - Astellas Medivation; Bayer; Bristol-Myers Squibb; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Roche
Research Funding - Ipsen
Travel, Accommodations, Expenses - BMS; BMS; Roche
 
Philippe Barthelemy
Honoraria - Astellas Pharma; Bayer; BMS; Gilead Sciences; IPSEN; Janssen-Cilag; Merck KGaA; MSD; Novartis; Pfizer; SEAGEN
Consulting or Advisory Role - AAA/Endocyte/Novartis; Amgen; AstraZeneca; Bayer; BMS; Eisai; Gilead Sciences; ipsen; Janssen-Cilag; Merck KGaA; MSD Oncology; Pfizer
Research Funding - IPSEN (Inst)
Travel, Accommodations, Expenses - BMS; IPSEN; Janssen-Cilag; Merck/Pfizer; MSD; Pfizer
 
Sylvie Negrier
Honoraria - Bristol-Myers Squibb; Eisai; Ipsen; MSD Oncology; Pfizer
Consulting or Advisory Role - Eisai; Ipsen; MSD Oncology
Research Funding - IPSEN (Inst); MSD (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; IPSEN; MSD; Pfizer
 
Stephane Oudard
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD Oncology; MSD Oncology; Novartis; Pfizer; Roche; Roche; Sanofi
Research Funding - AstraZeneca (Inst); Ipsen; Sanofi
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck; MSD Oncology; Novartis; Pfizer; Roche
 
Ricky Frazer
No Relationships to Disclose
 
Ronan Flippot
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; IPSEN; Johnson & Johnson/Janssen; Merck Serono; MSD Oncology; Pfizer
Consulting or Advisory Role - Bayer; Eisai; Ipsen; Janssen Oncology; Merck Serono; MSD Oncology; Pfizer
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Bayer; Merck/Pfizer; Merck/Pfizer
 
Laurence Albiges
Consulting or Advisory Role - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Europe GmbH (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - BMS; Ipsen; MSD; Pfizer